孟鲁司特联合布地奈德治疗过敏性鼻炎的临床疗效

Clinical Efficacy of Montelukast Combined with Budesonide in the Treatment of Allergic Rhinitis

目的探讨过敏性鼻炎患者采用孟鲁司特联合布地奈德治疗效果。方法纳入该院2017年8月—2018年8月收治的88例过敏性鼻炎患者,按照随机数字表法均分为两组,观察组44例给予孟鲁司特联合布地奈德治疗,对照组44例给予布地奈德治疗,比较两组治疗疗效,治疗前后症状评分和血清IL-6、IL-10、lgE水平。结果观察组治疗显效率和总有效率分别为68.18%、95.45%,显著高于对照组的50.00%、81.82%(χ~2=6.697、9.221,P<0.05);观察组治疗后的鼻炎症状评分、血清IL-6、IL-10、lgE水平分别为(1.51±0.85)分、(102.25±15.83)ng/L、(175.36±21.48)ng/L、(10.55±1.30)KU/L,显著优于对照组(t=9.184、7.882、2.607、11.804,P<0.05)。结论对于过敏性鼻炎患者,给予孟鲁司特联合布地奈德效果确切,可显著改善患者临床症状,可显著改善患者免疫功能,降低炎性表达,值得临床推广和使用。

Objective To investigate the effect of montelukast combined with budesonide in patients with allergic rhinitis.Methods 88 patients with allergic rhinitis admitted to our hospital from August 2017 to August 2018 were divided into two groups according to the random number table.44 patients in the observation group were treated with montelukast combined with budesonide.44 patients were treated with budesonide.The therapeutic effects of the two groups were compared.The symptom scores and serum IL-6,IL-10 and lgE levels were measured before and after treatment.Results The effective rate and total effective rate of the observation group were 68.18%and 95.45%,respectively,which were significantly higher than 50.00%and 81.82%of the control group(χ^2=6.697,9.221,P<0.05).The rhinitis symptoms score of the observation group after treatment of serum IL-6,IL-10 and lgE were(1.51±0.85)points,(102.25±15.83)ng/L,(175.36±21.48)ng/L,and(10.55±1.30)KU/L,respectively,better than the control group(t=9.184,7.882,2.607,11.804,P<0.05).Conclusion For patients with allergic rhinitis,the combination of montelukast and budesonide is effective,which can significantly improve the clinical symptoms of patients,can significantly improve the immune function of patients,reduce inflammatory expression,and is worthy of clinical promotion and use.